pixantrone has been researched along with Lymphoma, Non-Hodgkin in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (21.21) | 29.6817 |
| 2010's | 22 (66.67) | 24.3611 |
| 2020's | 4 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Glavey, S; Morris, J; Murphy, P; O'Reilly, M; Quinn, J; Sargent, J | 1 |
| Cencini, E; Fabbri, A | 1 |
| Bocchia, M; Cencini, E; Consoli, C; Cuccaro, A; De Marco, F; Fabbri, A; Ghio, F; Rocco, M; Simonetti, F | 1 |
| Bregni, M; de Barrenetxea Lekue, C; de Oteyza, JP; Grasso Cicala, S; Mombiedro, C; Navarro, B; Sancho, JM; Soler Campos, JA; Soler, B; Spione, M; Zinzani, PL | 1 |
| Menna, P; Minotti, G; Salvatorelli, E | 1 |
| Abastado, JP; Novack, SA; Perron, B; Therasse, P | 1 |
| Coiffier, B; Egorov, A; Pettengell, R; Singer, J; Sivcheva, L | 1 |
| Hübel, K | 1 |
| Długosz-Danecka, M; Jurczak, W; Rivas Navarro, F | 1 |
| Blajer-Olszewska, B; Chojnacki, T; Drozd-Sokołowska, J; Długosz-Danecka, M; Hus, I; Jurczak, W; Jurczyszyn, A; Puła, B; Raźny, M; Romejko-Jarosińska, J; Taszner, M | 1 |
| Dunder, K; Flores, B; Gisselbrecht, C; Hudson, I; Laane, E; Péan, E; Pignatti, F; Salmonson, T; Sjöberg, J | 1 |
| Hay, N; Landells, LJ; Prescott, C; Stevens, A; Sutcliffe, F | 1 |
| Boyle, EM; Morschhauser, F | 1 |
| Abastado, JP; Therasse, P | 1 |
| Hatswell, AJ; Kadambi, A; Lanitis, T; Muszbek, N; Patel, D; Pettengell, R; Singer, JW; Wang, L | 1 |
| Andorsky, D; Beck, JT; Belada, D; Dakhil, S; Daly, R; Dean, JP; Failloux, N; Georgiev, P; Hübel, K; Inhorn, LF; Pavlyuk, M; Pettengell, R; Quick, D | 1 |
| Barosi, G; Corradini, P; Martelli, M; Minotti, G; Oliva, S; Spina, M; Tura, S; Zinzani, PL | 1 |
| Keating, GM | 1 |
| El-Helw, LM; Hancock, BW | 2 |
| Mukherji, D; Pettengell, R | 2 |
| Friedrich, MJ | 1 |
| Borchmann, P; Cernohous, P; Engert, A; Herbrecht, R; Hess, G; Morschhauser, F; Singer, JW; Veals, SA; Wilhelm, M | 1 |
| Cohen, GI; Fayad, LE; Kuepfer, C; Liebmann, JE; Modiano, MR; Pro, B; Romaguera, JE; Singer, JW; Srokowski, TP | 1 |
| Jamal-Hanjani, M; Pettengell, R | 1 |
| Boland, G; Cernohous, P; Coiffier, B; de Mendoza, FH; Digumarti, R; Gomez, H; Gorbatchevsky, I; Kuepfer, C; Narayanan, G; Pettengell, R; Rizzieri, D; Schiller, G; Singer, JW; Wang, L; Zinzani, PL | 1 |
| Cabanillas, F | 1 |
| Papadatos-Pastos, D; Pettengell, R | 1 |
| Borchmann, P; Camboni, G; Engert, A; Gisselbrecht, C; Günther, H; Harousseau, JL; Morschhauser, F; Parry, A; Pfreundschuh, DM; Rudolph, C; Schnell, R; Wilhelm, M | 1 |
| Borchmann, P; Schnell, R | 1 |
| Engert, A; Gorbatchevsky, I; Herbrecht, R; Santoro, A; Zinzani, PL | 1 |
| Bernareggi, A; Borchmann, P; Camboni, GM; Diehl, V; Engert, A; Hübel, K; Knippertz, R; Schnell, R; Schulz, A; Staak, JO; Staib, P | 1 |
10 review(s) available for pixantrone and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Topics: Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Prognosis; Topoisomerase II Inhibitors | 2018 |
The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunotherapy, Adoptive; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Stem Cell Transplantation | 2019 |
Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.
Topics: Adult; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2016 |
Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Isoquinolines; Lymphoma, Non-Hodgkin | 2009 |
Pixantrone maleate for non-Hodgkin's lymphoma.
Topics: Adult; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Topoisomerase II Inhibitors | 2009 |
Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Isoquinolines; Lymphoma, Non-Hodgkin | 2010 |
Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Topics: Anthracyclines; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Drug Evaluation; Humans; Isoquinolines; Lymphoma, Non-Hodgkin | 2011 |
Pixantrone: merging safety with efficacy.
Topics: Clinical Trials, Phase II as Topic; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Topoisomerase II Inhibitors | 2013 |
The role of pixantrone in the treatment of non-Hodgkin's lymphoma.
Topics: Animals; Antineoplastic Agents; DNA Topoisomerases, Type II; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Topoisomerase II Inhibitors | 2005 |
Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Neutropenia; Thrombocytopenia; Topoisomerase II Inhibitors | 2007 |
9 trial(s) available for pixantrone and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
Topics: Adult; Aged; Europe; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Treatment Outcome | 2018 |
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Disease-Free Survival; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Quality-Adjusted Life Years; Recurrence; Retreatment; Secondary Prevention; Survival Rate; United Kingdom | 2016 |
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Research Design; Rituximab | 2016 |
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Recurrence; Survival Analysis; Treatment Outcome; Vincristine | 2011 |
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Vidarabine | 2011 |
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy; Ventricular Function, Left | 2012 |
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Recurrence; Thrombocytopenia; Topoisomerase II Inhibitors; Treatment Outcome | 2003 |
EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Relapsing Fever | 2006 |
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Treatment Outcome | 2001 |
14 other study(ies) available for pixantrone and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Pixantrone as a bridge to CAR-T treatment in high-grade transformation of follicular lymphoma.
Topics: Humans; Isoquinolines; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen | 2022 |
Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional TUSCAN Lymphoma Network)-Authors' reply to Morris and colleagues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Retrospective Studies; Rituximab | 2022 |
Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Retrospective Studies | 2023 |
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
Topics: Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Retreatment; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome | 2020 |
Do You Know Pixantrone?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Prednisone; Stem Cell Transplantation; Vincristine | 2017 |
The Servier oncology pipeline in 2017.
Topics: Apoptosis; Drug Discovery; Drug Industry; France; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Medical Oncology; Protein Kinase Inhibitors; Trifluridine | 2017 |
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous | 2019 |
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human u
Topics: Adult; Anthracyclines; Drug Approval; European Union; Female; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Meta-Analysis as Topic; Recurrence; Risk Assessment; Treatment Outcome | 2013 |
NICE guidance on pixantrone monotherapy for multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
Topics: Cost-Benefit Analysis; Drug Approval; Drug Costs; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Practice Guidelines as Topic; Recurrence; Topoisomerase II Inhibitors; Treatment Outcome | 2014 |
Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Time Factors; Treatment Outcome | 2015 |
Servier's pipeline in oncology: moving from research to patients.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell- and Tissue-Based Therapy; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Discovery; Drug Industry; Humans; Immunotherapy; Isoquinolines; Lymphoma, Non-Hodgkin; Medical Oncology; Neoplasms; Precision Medicine; Protein Engineering; Protein Kinase Inhibitors; Public-Private Sector Partnerships; Topoisomerase II Inhibitors; Translational Research, Biomedical | 2016 |
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Management; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Practice Guidelines as Topic; Recurrence; Topoisomerase II Inhibitors | 2016 |
Lymphoma researchers in search of molecular targets.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials as Topic; Drug Approval; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Signal Transduction; United States; United States Food and Drug Administration | 2010 |
Pixantrone: a new agent for relapsed aggressive lymphomas.
Topics: Antineoplastic Agents; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Salvage Therapy | 2012 |